Clinical Trials in Philadelphia

Showing 4101-4120 of 20,904 trials

STXBP1 and SYNGAP1 Related Disorders Natural History Study

NCT06555965

The purpose of this study is to find out more about STXBP1 and SYNGAP1 related disorders. The information gathered by this study will be used to prepare for clinical treatment trials. The primary objective of the study is to better define and outline the clinical spectrum of STXBP1 and SYNGAP1 through detailed developmental, seizure, and quality of life assessments as an extension of routine clinical care.

Genetic DiseaseSTXBP1 Encephalopathy With EpilepsySYNGAP1-Related Intellectual Disability

Children's Hospital of Philadelphia600 participantsStarted Aug 2023

Palo Alto, California, United States • Aurora, Colorado, United States • New York, New York, United States +2 more locations

RECRUITINGPhase 1< 1 mile

Adaptive Radiation for Abdominopelvic Metastases

NCT05880667

Single arm Phase I trial of adaptive stereotactic body radiation (SBRT) for abdominopelvic metastases. Adaptive SBRT will allow for escalation of the prescription dose and target coverage while maintaining grade 3+ toxicity no greater than 10%. Subjects with metastatic cancer to the abdomen or pelvis requiring local control or palliation will be enrolled.

Neoplasm - Soft Tissue Pelvis Malignant SecondaryMalignant Neoplasm of Stomach

Fox Chase Cancer Center30 participantsStarted Aug 2023

Philadelphia, Pennsylvania, United States

STXBP1 and SYNGAP1 Related Disorders Natural History Study

Adaptive Radiation for Abdominopelvic Metastases

Find Trials by Condition in Philadelphia

Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Fetoscopic Endoluminal Tracheal Occlusion in Severe Left Congenital Diaphragmatic Hernia

Tau PET Imaging in the NACC Study Cohort

Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

Effects of P-TIOX and Tixel Combined on Reducing Eye Wrinkles

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma

Individualizing Treatment for Asthma in Primary Care (Full Study)

Sulforaphane in a New Jersey (NJ) Population of Individuals With Autism

Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage

Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

Virtue® SAB in the Treatment of Coronary ISR Trial

Access Cannulation Trial II

Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC